17.92
price down icon0.44%   -0.08
after-market Dopo l'orario di chiusura: 17.92
loading
Precedente Chiudi:
$18.00
Aprire:
$17.98
Volume 24 ore:
1.29M
Relative Volume:
0.94
Capitalizzazione di mercato:
$1.76B
Reddito:
-
Utile/perdita netta:
$-44.84M
Rapporto P/E:
-38.13
EPS:
-0.47
Flusso di cassa netto:
$-44.23M
1 W Prestazione:
-2.34%
1M Prestazione:
+6.79%
6M Prestazione:
+27.27%
1 anno Prestazione:
+72.31%
Intervallo 1D:
Value
$17.70
$18.16
Intervallo di 1 settimana:
Value
$17.52
$18.61
Portata 52W:
Value
$8.9055
$18.90

Ars Pharmaceuticals Inc Stock (SPRY) Company Profile

Name
Nome
Ars Pharmaceuticals Inc
Name
Telefono
858-771-9307
Name
Indirizzo
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Name
Dipendente
160
Name
Cinguettio
Name
Prossima data di guadagno
2024-12-13
Name
Ultimi documenti SEC
Name
SPRY's Discussions on Twitter

Confronta SPRY con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SPRY
Ars Pharmaceuticals Inc
17.92 1.73B 0 -44.84M -44.23M -0.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-07 Iniziato Scotiabank Sector Outperform
2025-02-10 Iniziato Oppenheimer Outperform
2024-08-20 Iniziato Cantor Fitzgerald Overweight
2024-08-13 Aggiornamento Raymond James Outperform → Strong Buy
2024-08-12 Reiterato Leerink Partners Outperform
2024-07-25 Iniziato Raymond James Outperform
2024-03-05 Aggiornamento Leerink Partners Market Perform → Outperform
2024-02-20 Aggiornamento William Blair Mkt Perform → Outperform
2023-09-20 Downgrade William Blair Outperform → Mkt Perform
2023-01-31 Iniziato Wedbush Outperform
2023-01-03 Iniziato William Blair Outperform
2022-12-13 Iniziato SVB Leerink Outperform
Mostra tutto

Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie

pulisher
Jul 24, 2025

Is ARS Pharmaceuticals Inc. a good long term investmentTriple-digit return opportunities - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 23, 2025

ARS Pharmaceuticals Inc. Stock Analysis and ForecastStrong return on assets - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What drives ARS Pharmaceuticals Inc. stock priceTremendous growth opportunities - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about ARS Pharmaceuticals Inc. stockBreakthrough stock performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

MHRA approves needle-free adrenaline nasal spray for anaphylaxis - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

EURneffy® (adrenaline nasal spray) Approved in the U.K. as - GlobeNewswire

Jul 18, 2025
pulisher
Jul 18, 2025

Revolutionary Needle-Free Alternative to EpiPen Approved in UK: EURneffy Changes Anaphylaxis Treatment - Stock Titan

Jul 18, 2025
pulisher
Jul 15, 2025

ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy? - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High? - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing' - Yahoo Finance

Jul 15, 2025
pulisher
Jul 10, 2025

ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine (SPRY) - Seeking Alpha

Jul 10, 2025
pulisher
Jul 09, 2025

(SPRY) Technical Data - news.stocktradersdaily.com

Jul 09, 2025
pulisher
Jul 09, 2025

ARS Pharmaceuticals: 'Betting On The Come' (NASDAQ:SPRY) - Seeking Alpha

Jul 09, 2025
pulisher
Jul 03, 2025

ARS Pharmaceuticals: Insider Liquidity vs. Institutional Buying – A Contrarian Opportunity? - AInvest

Jul 03, 2025
pulisher
Jul 01, 2025

ARS Pharmaceuticals: Navigating Insider Sales Amid Growth Catalysts - AInvest

Jul 01, 2025
pulisher
Jun 30, 2025

Raymond James reiterates strong buy on ARS Pharmaceuticals stock - Investing.com India

Jun 30, 2025
pulisher
Jun 27, 2025

ARS Pharmaceuticals (SPRY) Soars 4.48% on Earnings, Partnership - AInvest

Jun 27, 2025
pulisher
Jun 26, 2025

ARS Pharmaceuticals Holds 2025 Annual Stockholders Meeting - TipRanks

Jun 26, 2025
pulisher
Jun 23, 2025

High Growth Tech Stocks in US for June 2025 - simplywall.st

Jun 23, 2025
pulisher
Jun 21, 2025

Ars pharma CCO Karas sells $240k in SPRY stock - Investing.com India

Jun 21, 2025
pulisher
Jun 18, 2025

Learn to Evaluate (SPRY) using the Charts - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 18, 2025

ARS Pharmaceuticals | 6/18/25 - ktnv.com

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Reviewing Oral Epinephrine Film for Possible Approval - Allergic Living

Jun 18, 2025
pulisher
Jun 17, 2025

Asthma Market to Expand Significantly by 2034, States - openPR.com

Jun 17, 2025
pulisher
Jun 17, 2025

Asthma Market to Expand Significantly by 2034, States DelveInsight Report | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech - Barchart.com

Jun 17, 2025
pulisher
Jun 15, 2025

ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy - MSN

Jun 15, 2025
pulisher
Jun 15, 2025

Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier” - Insider Monkey

Jun 15, 2025
pulisher
Jun 12, 2025

Jim Cramer Discussed These 16 Stocks Recently - Insider Monkey

Jun 12, 2025
pulisher
Jun 09, 2025

ARS Pharmaceuticals Earns Relative Strength Rating Upgrade - Investor's Business Daily

Jun 09, 2025
pulisher
Jun 06, 2025

Long Term Trading Analysis for (SPRY) - news.stocktradersdaily.com

Jun 06, 2025
pulisher
Jun 05, 2025

Bank of America Corp DE Has $1.70 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World

Jun 05, 2025

Ars Pharmaceuticals Inc Azioni (SPRY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):